CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Update

CytoMed Therapeutics Limited (NASDAQ:GDTCGet Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 35,300 shares, a drop of 8.3% from the May 15th total of 38,500 shares. Based on an average daily volume of 6,100 shares, the short-interest ratio is currently 5.8 days. Approximately 0.8% of the shares of the stock are sold short.

CytoMed Therapeutics Stock Down 4.6 %

CytoMed Therapeutics stock traded down $0.09 during midday trading on Wednesday, hitting $1.94. 6,603 shares of the company’s stock were exchanged, compared to its average volume of 2,534. The company has a quick ratio of 14.09, a current ratio of 14.09 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average of $2.09 and a two-hundred day moving average of $2.75. CytoMed Therapeutics has a 12 month low of $1.89 and a 12 month high of $9.25.

Analysts Set New Price Targets

Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of CytoMed Therapeutics in a report on Tuesday, June 11th.

Get Our Latest Research Report on CytoMed Therapeutics

CytoMed Therapeutics Company Profile

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.

Recommended Stories

Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with's FREE daily email newsletter.